Solid Biosciences (SLDB) was upgraded by Truist Financial Corporation to "strong-buy".
Solid Biosciences (SLDB) had its price target raised by JPMorgan Chase & Co. from $11.00 to $12.00. They now have an "overweight" rating on the stock.
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Solid Biosciences (SLDB) is now covered by Guggenheim. They set a "buy" rating and a $26.00 price target on the stock.
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.